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Purpose: Clusterin (CLU), an antiapoptotic, stress-associated pro-
tein, confers resistance to therapy when overexpressed. This trial
tested custirsen (OGX-011), an inhibitor of CLU protein production,
combined with gemcitabine/platinum in patients with advanced
non-small cell lung cancer (NSCLC).
Patients and Methods: This was a single-arm, multicenter, phase
I/II study in chemotherapy-naive stage IIIB/IV NSCLC. Custirsen
was infused during a loading dose period and weekly in combination
with gemcitabine (1250 mg/m2) on days 1 and 8 and with cisplatin
(75 mg/m2) or carboplatin (area under the curve 5) on day 1 of each
21-day cycle. Ten patients were treated in a phase I lead-in and 71
in the phase II component. The primary efficacy endpoint was
response rate, with exploratory analyses of other efficacy outcomes
and biomarker relationships.
Results: Eighty-one patients received custirsen and were included in
the primary analysis. The median age was 61 years; 82% had stage IV
disease. Overall response was 25 of 81 (31%; 95% confidence interval
21–42). The 1- and 2-year survivals were 54 and 30%, respectively.
Toxicity of the combination was not appreciably different from what is
reported for gemcitabine/platinum combinations. Custirsen treatment
decreased serum CLU levels in 95% of patients evaluated. Patients who
achieved a minimum median CLU level for the population of 38
g/ml during treatment had a median survival of 27.1 compared with
16.1 months for patients who did not (p  0.02).
Conclusion: Based on the above results, a randomized phase 3 trial
to evaluate the survival benefit of custirsen in patients with NSCLC
is warranted.
Key Words: Advanced NSCLC, Antisense oligonucleotide, Novel
therapeutics, Chemotherapy, Biomarker.
(J Thorac Oncol. 2012;7: 579–586)
Development of resistance to chemotherapy commonlyoccurs during treatment of cancers. One pathway to
resistance is the up-regulation of pro-cell-survival proteins
that seem to promote tumor progression and facilitate tumor
resistance by inhibiting apoptosis.1 One such protein is clus-
terin (CLU), an antiapoptotic, stress-associated protein that is
cytoprotective and confers resistance to treatment when over-
expressed.2–6 More than 70% of human non-small cell lung
cancers (NSCLCs) are positive for CLU by immunohisto-
chemistry.7,8
In preclinical and prior clinical trials, custirsen sodium
(OGX-011; OncoGenex Technologies Inc., Vancouver, BC,
Canada), a second generation antisense oligonucleotide
(ASO), has been shown to decrease the expression of CLU in
cancer cells by hybridizing CLU mRNA and inhibiting pro-
duction of CLU protein.9,10 Custirsen has a 21-mer phospho-
rothioate backbone similar to first-generation ASOs.11 How-
ever, the addition of methoxyethyl groups affords increased
affinity for the target mRNA, increased potency, and pro-
longed tissue half-life, allowing for weekly dosing.9,10 Cu-
stirsen has been shown to decrease CLU expression in A549
cells by greater than 75% in a dose-dependent, sequence-
specific manner.7 Custirsen suppression of CLU also en-
hanced sensitivity to chemotherapies such as paclitaxel and
gemcitabine both in vitro and in vivo in several lung cancer
models.7,12 In vivo studies demonstrated significant delay in
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tumor growth in A549 xenografts when custirsen plus che-
motherapy was compared with chemotherapy alone.9
Prior studies have looked at the prognostic role of CLU
in NSCLC. In one, the expression of CLU was significantly
related to pathologic differentiation, clinical stage, and lymph
node metastasis but not to sex or histologic type.8
Supported by preclinical data that custirsen signifi-
cantly decreases CLU production, increases sensitivity of
lung cancer cells to chemotherapies, and delays growth of
cancers in lung cancer models, this phase I/II study was
designed to assess safety and response rate, as the primary
objectives, when custirsen was combined with gemcitabine/
platinum as first-line therapy in patients with chemotherapy-
naive, IIIB/IV NSCLC. Secondary objectives included pro-
gression-free survival (PFS), overall survival (OS), and the
effect of custirsen on serum CLU levels. Exploratory analy-
ses evaluated the association of serum CLU changes with
survival outcome.
PATIENTS AND METHODS
Patient Eligibility
Patients with NSCLC were eligible if they had histo-
logically/cytologically confirmed IIIB (N3 and/or pleural or
pericardial effusion) or IV disease not amenable to treatment
with curative intent. No prior chemotherapy or biological
therapy was allowed, but patients could have received prior
radiation therapy providing that: the lesion used for response
determination had not been previously irradiated or had
increased in size since radiotherapy; radiotherapy had been
completed at least 2 weeks before treatment (6 weeks for
lesions used to determine response); and the patient had
recovered from all toxicities. Additional eligibility require-
ments included: age18 years; at least one unidimensionally
measurable lesion meeting RECIST criteria13; an Eastern
Cooperative Oncology Group performance status (PS) of1;
and adequate hematologic, hepatic, and renal function. Pa-
tients were excluded if they were pregnant, had leptomenin-
geal disease or untreated central nervous system metastases,
active infection, serious systemic disorder, or second malig-
nancy. Written informed consent was required. The study was
approved by ethical committees at all participating institu-
tions and filed with the U.S. Food and Drug Administration as
an Investigational New Drug Application and with Health
Canada as a Clinical Trial Application.
Study Design and Treatment
Prior phase I studies showed that 640 mg of custirsen
was the biologically effective dose, that is, the dose at which
tumors demonstrated a 92% reduction of CLU mRNA,10 and
that custirsen was well tolerated in conjunction with do-
cetaxel chemotherapy.14 Thus, the current trial was initiated
with a 10-patient safety phase I lead-in to assess pharmaco-
kinetics (PK) and tolerability of custirsen with cisplatin/
gemcitabine. Three patients were treated at the 480-mg and
seven patients at the 640-mg target dose. The starting dose of
custirsen was 640 mg for patients in the phase II part of the
study.
Patients could receive up to six cycles of therapy. Cu-
stirsen was infused intravenously (IV) over 2 hours during a
loading dose period (three doses on days 7, 5, and 3) and
then weekly on days 1, 8, and 15 of each 21-day cycle. Gem-
citabine (1250 mg/m2) was infused IV over 30 minutes on days
1 and 8 and cisplatin (75 mg/m2) over 1 hour on day 1.
Carboplatin (area under the curve of 5) was allowed as an
alternative to cisplatin in the phase II portion. Doses were to be
held or reduced for both chemotherapy and custirsen for the
following: febrile neutropenia, grade 4 neutropenia lasting 7
days, grade 4 thrombocytopenia, bleeding withgrade 2 throm-
bocytopenia, grade 4 nausea and vomiting, grade 3 partial
thrombin time/international normalized ratio,grade 3 aspartate
amino-transferase or alanine amino-transferase, grade 2 bili-
rubin, serum sodium125 mmol/liter, creatinine clearance35
ml/min, or any other grade 3/4 toxicity other than alopecia.
There were separate dose modifications for gemcitabine for
stomatitis and diarrhea. Therapy was discontinued if more than
two dose reductions were required or if there was more than a
2-week delay in therapy because of toxicity. All patients re-
ceived standard supportive care and blood product support.
Hematologic growth factors were permitted.
Study Assessments
Baseline evaluations included a history and physical
examination, PS, routine biochemical, hematologic and co-
agulation analyses, and a pregnancy test, if applicable. Base-
line tumor assessments included computer tomography scans
of the chest, abdomen, and pelvis, plus bone scans when
clinically indicated. Tumor assessments were performed fol-
lowing cycles 2, 4, and 6 and subsequently every 2 months
until disease progression, initiation of new anticancer therapy
or death.
Safety evaluations included monitoring of vital signs
during custirsen infusions, and repeat baseline evaluations
were performed during the first loading dose visit, on day
1 only or days 1 and 8 of each cycle of therapy, and at an
“End of Treatment” visit. Adverse events (AEs) and con-
comitant medications were recorded at each weekly visit
and 30 days after the last dose of study treatment. Toxicity
was graded according to the National Cancer Institute
Common Terminology Criteria for AEs V3.0. Once treat-
ment was discontinued, safety assessments were obtained
at each disease evaluation visit until disease progression.
An independent medical oncologist reviewed all available
information for safety after the first 43 patients were
enrolled in phase II.
In both the phase I and II parts of the study, serum CLU
samples were collected at baseline and on day 1 of cycles 2
and 3 before any treatment. Samples were analyzed at Mayo
Clinical Trial Services (Rochester, MN) using a solid-phase,
enzyme-linked immunosorbent assay (ELISA) in microplate
format designed for the quantitative measurement of human
CLU in serum and plasma (BioVendor Clusterin ELISA, Ann
Arbor, MI).
Blood samples for custirsen, gemcitabine, and cisplatin
PK studies were collected from all phase I patients at fixed
times with a total of eight samples starting at 0.5 hours and
ending at 24 hours. Quantitation of custirsen was analyzed by
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a hybridization-dependent nuclease ELISA at Charles River
Laboratories. Quantitation of gemcitabine and cisplatin in
plasma was analyzed by high-performance liquid chromatog-
raphy mass spectrometry at the Prostate Center at Vancouver
General Hospital Investigational Drug Program.
Statistical Considerations
The primary objective of the study was to estimate
the proportion of patients responding (complete response
[CR] and partial response [PR] to custirsen in combination
with gemcitabine/platinum. It was assumed that the com-
bination being evaluated would be of further interest if the
data supported a true response probability of 20%.15 The
accrual target was 70 evaluable patients (phase I and II).
The phase II portion of the study included a futility test
when 43 eligible and evaluable patients had been accrued.
Rejection of the futility null hypothesis corresponded to 5
or fewer responses (11.6% or less responding). The pri-
mary analysis population was defined as all patients treated
with study drug. The worst degree of toxicity experienced
by a patient during the study was computed. Tumor re-
sponse and disease progression were based on RECIST.16
PFS was defined as the time from the date of first study
treatment to the date of documented disease progression or
death. For patients without disease progression who initi-
ated subsequent anticancer therapy, the date of progression
was defined as the date of new cancer treatment. PFS was
censored at the date of the first study treatment for patients
who failed to return for disease assessments and at the last
disease assessment for patients who were still alive with-
out disease progression at the end of the study. OS was
defined as the time from the date of first study treatment to
the date of death from any cause; OS time was censored at
the date of last contact for patients who were still alive.
Proportional hazard regression analyses were performed
to assess the relationship between survival and serum CLU
levels. Only patients with a baseline and at least one CLU level
during treatment were included in the analyses (i.e., the CLU
analysis population). During treatment, a CLU response was
defined as having a minimumCLU level less than or equal to the
median minimum CLU level for the population (38 g/ml).
The starting survival model included the following terms: base-
line CLU (categorized as below and above the median baseline
CLU for the population), CLU response, and any interaction.
The model reported is the result of a step-down procedure using
a 0.1 criteria for exclusion of terms.
To evaluate the robustness of the conclusion, a 30-day
(approximately cycle 2, day 1) landmark analysis was also
performed where only patients with CLU data available at the
day-30 landmark were included in the analysis to reduce the bias
related to censoring because of early withdrawal. Ideally, these
analyses should be performed using proportional hazard model-
ing with a time-dependent covariate, as was done in a previous
phase II study in patients with prostate cancer that evaluated
serial CLU17; however, the data collected after cycle 2 in this
study were too sparse to allow this type of analysis. To assess the
consistency of the results between this study and the previous
prostate cancer study, analyses were performed on the CLU
analysis population for a CLU response defined as achieving a
“threshold” minimum CLU level 45 g/ml during treatment
(a threshold target defined from the previous prostate cancer
study).
Finally, Kaplan-Meier (KM) estimates for all patients
evaluable in the CLU analysis population (n 55) and for the
30-day landmark subpopulation (n  49) were plotted for
CLU responders versus nonresponders. Survival by the
above-described classification was compared using a median
estimate and the log-rank test.
RESULTS
Patient Demographics and Disease
Characteristics
Eighty-five patients were enrolled between November
2004 and November 2006 at 15 sites in the United States and
Canada. All patients have been followed for a minimum of 3
years. In the phase I safety component of the study, three
patients were treated with custirsen at a dose of 480 mg and
seven patients at 640 mg. Higher doses were not tested. Three of
10 achieved a PR. As there was no dose-limiting toxicity, the
dose for the phase II portion was set at 640 mg. On the basis of
evaluation performed after the first 43 patients were enrolled and
the observation that 13 of the 43 patients (30%) had an objective
response, the study was continued as planned. Subsequently, 32
more patients were enrolled.
Table 1 shows the baseline characteristics. The median
age was 61 years and 51% were male. The majority of
patients had stage IV disease (81%) and an Eastern Cooper-
ative Oncology Group PS of 1 (68%).
Treatment
Of the 85 patients entered on trial, 81 received at least
one dose of study drug and were included in the primary
analysis. Four patients never received study drug because of
decreased PS (2), positive pregnancy test (1), and cerebro-
TABLE 1. Patient Demographics and Disease Characteristics
at Baseline
Characteristic n  81
Age (yr), median (range) 61 (43–79)
Gender (%)
Male 51
Female 49
Stage (%)
IIIB 19
IV 81
Visceral metastases (%) 23
Histology (%)
Adenocarcinoma 51
Squamous cell 16
Undifferentiated/unspecified NSCLC 33
ECOG performance status (%)
0 32
1 68
Prior radiation therapy (%) 31
NSCLC, non-small cell lung cancer; ECOG, Eastern Cooperative Oncology Group.
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vascular accident (CVA) during screening (1). Seventy-five
of 81 (93%) patients received custirsen and at least one dose
of chemotherapy. Six were removed from study before the
start of chemotherapy for disease progression (2), withdrawal
of consent (1), and AEs (3) but were included in the primary
analyses. Sixty of 75 (80%) patients who received chemo-
therapy initially received cisplatin and 15 (20%) received
carboplatin. Nine of 60 (15%) on cisplatin were switched to
carboplatin because of an AE. Sixty-one of 81 (75%) patients
discontinued study drug before the end of cycle 6: 21 (26%)
for disease progression, 11 (14%) at the discretion of the
treating physician, 5 (6%) for withdrawal of consent, 23
(28%) as the result of an AE, and 1 (1%) died. The most
common AEs causing discontinuation of study drug were
hematologic toxicity and fatigue. The mean relative dose
intensity was 92% for custirsen, 85% for gemcitabine, and
94% for the two platinum compounds.
Information on treatment after progression was pro-
spectively collected and available for all patients. For the 46
(57%) who received second-line chemotherapy, the median
time to treatment was 2.6 months from the last study drug
administration. For these 46 patients, treatment included
erlotinib (16 patients), docetaxel regimen (12 patients), and
pemetrexed regimen, gemcitabine/platinum regimen, and
“other” (6 each).
Efficacy
Tumor response to custirsen in combination with gem-
citabine/platinum occurred in 25 of 81 (31%) patients (95%
confidence interval [CI] 21–42), with 1 CR and 24 PRs.
Fifty-six (69%; 95% CI 58–79) had a clinical response
(objective response and stable disease). Thus, the estimate of
the proportion of patients responding met the prespecified
success criterion of being consistent with a greater than 20%
probability of response. The median PFS was 4.3 months
(95% CI 3.0–5.3) and OS was 14.1 months (95% CI 9.4–
17.5; Figure 1). One- and 2-year KM survival rates were 54%
(95% CI 43–64) and 30% (95% CI 21–40), respectively.
There were no significant differences in the response rate or
PFS when the three patients in the phase I portion of the trial
who received a lower dose of custirsen (480 mg) were
removed from the analysis. Because two of the three patients
in the 480 mg group had very long survival times, the median
survival did change from 14.1 (n  81) to 13.0 months (n 
78), but the 1- and 2-year survival rates remained unchanged.
Toxicity
Fourteen (1%) custirsen infusions were interrupted or
discontinued, and 1% were modified for toxicity. During the
initial loading dose period, in which custirsen was adminis-
tered without chemotherapy, symptoms of chills and pyrexia
were seen in approximately half the patients; 96% were grade
1 or 2.
The three AEs during this loading dose period causing
removal from study treatment were hypotension after infu-
sion, increased liver enzymes, and myocardial infarction.
Infusion reactions were not seen outside the initial loading
dose period.
The most common treatment-related nonhematologic
AEs, in decreasing order, included nausea, fatigue, chills,
pyrexia, vomiting, decreased appetite, dysgeusia, alopecia,
and constipation. Eighty-six percent were grade 1 or 2. There
were two uncommon AEs: thrombotic thrombocytopenic
purpura (reported to be associated with gemcitabine18) and
acute cortical blindness (reported to be associated with cis-
platin19,20). Table 2 lists all hematologic and nonhematologic
grade 3 AEs seen in 5% of patients. The most common
serious AEs requiring hospitalization were pleural effusion,
dyspnea, and CVA.
Hematologic toxicity was frequently observed. The
degree of hematologic toxicity appeared to vary with the
platinum agent administered, with more grade 4 neutropenia
FIGURE 1. Kaplan-Meier survival
curve for all patients (n  81).
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and thrombocytopenia in patients treated with carboplatin.
Febrile neutropenia was documented in three patients; serious
infections (pneumonia, empyema, bacteremia, and septice-
mia) in four; and grade 3 hemorrhage (epistaxis and gastro-
intestinal bleed) in two. The incidence of treatment with
hematopoietic growth factors was 15% and with platelet
transfusions was 10%.
Four patients died within 90 days of study entry due to
septicemia (1), myocardial infarction (1), cardiac-related
event (1), and stroke (1). Only the septicemia was deemed to
be possibly related to study therapy.
Serum Clusterin Correlations with Survival
Serum CLU samples were collected at baseline and
before treatment on day 1 of cycles 2 and 3. Of the 81
patients, 69 had baseline CLU levels and 55 of 69 also had at
least one CLU assessment during treatment and were in-
cluded in the CLU analysis population.
Baseline CLU levels.
The baseline mean and standard error and the baseline
median for CLU in the CLU analysis population were 65.2
3.7 g/ml and 54.0 g/ml, respectively. For the 14 patients
who only had CLU levels at baseline, the mean and standard
error and the median for CLU were 62.7  4.8 g/ml and
57.5 g/ml, respectively.
CLU levels during treatment.
Custirsen treatment significantly reduced serum CLU
levels by day 1 of cycle 2 or 3, with 52 of the 55 patients
(95%) having a reduction in CLU during treatment compared
with their baseline level. The mean reduction from baseline
was 25.1 g/ml, p  0.0001 (baseline versus minimum CLU
during treatment, paired t test).
CLU levels and survival analyses.
For the 69 patients with baseline serum CLU levels,
median survival was 14.9 months. Missing levels during
treatment in the 14 patients who had only baseline CLU
levels were primarily due to study discontinuation before
cycle 2. As expected, these 14 patients had a worse survival,
with a median survival time of 2.4 months, compared with
18.8 months for the 55 patients who reached at least day 1,
cycle 2.
Baseline CLU was not found to be a prognostic vari-
able, that is, it was not associated with survival when evalu-
ated in all 69 patients with a baseline CLU level, in 55
patients who had both baseline and at least 1 CLU assessment
during treatment (CLU analysis population), or in the 49
patients evaluable for the 30-day landmark analysis (30-day
landmark subpopulation). The model resulting from the step-
down selection for the analyses included only CLU response
as an independent variable. Figure 2 shows the Kaplan-Meier
estimates for both the CLU analysis population and the
30-day landmark subpopulation regarding CLU responders
and nonresponders. For both analyses, the estimated ratio of
death hazard rate for those classified as having a CLU
response to the death hazard rate for those not having a
response was 0.5, representing a 50% reduction in the hazard
of death with a CLU response.
When the analysis was repeated for the CLU analysis
population using another CLU response definition from a
previous prostate cancer study (i.e., achieving a “threshold”
minimum CLU level 45 g/ml during treatment), the re-
sults remained the same (Table 3) and showed a consistently
longer survival time for patients having a CLU response. Of
the 55 patients in the CLU analysis population, 35 (64%)
achieved a threshold minimum serum CLU level of 45
g/ml during treatment and had a median survival of 27.1
months compared with the 20 (36%) who did not achieve a
threshold minimum CLU level of 45 g/ml and had a
median survival of 15.6 months (p  0.02).
Custirsen Pharmacokinetic Studies
The mean AUC0-inf was 149.4 gh/ml for the 480-mg
dose and 260.7 gh/ml for the 640-mg dose. Clearance was
3.3 and 2.5 liter/h, respectively. The terminal half-life was 3.7
hours at the 640-mg dose. CLU was quantifiable in all
postdose samples for up to 25.5 hours. Gemcitabine and
cisplatin PK profiles seemed not to be affected by the addition
of custirsen.
DISCUSSION
Lung cancer remains the leading cause of cancer death
in North America.21 We tested a strategy to target acquired
chemotherapy resistance resulting from stress-induced up-
regulation of cytoprotective molecular chaperones like CLU.
CLU has multiple mechanisms of action that promote cell
survival and confer broad-spectrum treatment resistance. As
examples, CLU is involved in the inhibition of endoplasmic
TABLE 2. Grade 3 or Higher AEs Observed in 5% of
Patients by Toxicity Grade (n  81)
Toxicitya Grade 3 (%) Grade 4 (%)
Neutropeniab 30 21
Leukopeniab 40 6
Thrombocytopeniab 11 22
Lymphopeniab 32 1
Hyponatremiab 22 1
Dyspnea 20
Fatigue 16
Anemiab 14
Vomiting 11
Hypokalemiab 10 1
Nausea 10
Pleural effusion 7
Pulmonary embolism 2 5
Elevated ALTb 6
Decreased appetite 6
Arthralgia 5
Chest pain 5
Hypophosphatemiab 5
Hypoxia 4 1
a Percent of patients experiencing an event.
b Laboratory events based on actual laboratory values recorded.
AE, adverse event.
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reticulum vacuolization and protein aggregation under
stress22,23; interaction with and inhibition of activated
Bax24; and enhancement of COMMD1 and Ik-B degrada-
tion, thereby enhancing nuclear factor-kB transcriptional
activity.25,26
Custirsen is a second-generation ASO to CLU mRNA.
A major limitation of first-generation ASOs was the require-
ment for continuous IV infusion because of the short tissue
half-life. The stability and efficacy of second-generation
ASOs has been improved by modifications of the phosphodi-
ester linkage.27 The formation of duplexes with RNA with
significantly higher affinity and with improved resistance
against nuclease-mediated metabolism results in improved
tissue half-life.28
In this study, custirsen was administered in combina-
tion with a gemcitabine/platinum doublet as first-line therapy
for advanced NSCLC. Unlike many studies, survival data are
mature with a minimum follow-up of 3 years. The median OS
was 14.1 months, and the 1- and 2-year survivals were 54 and
30%, with 12% still alive for a median of 41 (range 38–59)
months. The major limitation of this study is the lack of a
comparator arm. However, the survival data in this multi-
center trial compare quite favorably with published data of
patients receiving a gemcitabine/platinum-based regimen in a
similar dose and schedule, with median survivals of 7 to 11
months, 1-year survival rates of 37 to 43%, and 2-year
survival rates of 20%.29–37
Exploratory analyses were performed on survival and
changes in serum CLU levels from baseline during custirsen
treatment. CLU levels decreased in 95% of patients after
custirsen treatment, by an average of 25.1 g/ml (35%; p 
0.0001). This is not an isolated finding as custirsen had a
notable effect on lowering serum CLU in three prior studies
in patients with prostate cancer.10,14,17 Most importantly,
achieving a serum CLU response even after only one cycle of
therapy, defined as achieving levels 38 g/ml (the median
minimal level for the population) was shown to be associated
with a reduced risk of death of 50% (hazard ratio of 0.5). In
addition, using the serum threshold level of 45 g/ml as
identified in the phase 2 study in prostate cancer, was also
associated with longer survival, suggesting that this effect is
not isolated to one tumor type.17 Larger randomized phase III
FIGURE 2. Survival analyses of patients with and without a clusterin (CLU) response during treatment Kaplan-Meier esti-
mates for the CLU analysis population and the 30-day landmark subpopulation for CLU responders and nonresponders.
TABLE 3. Effect of Serum Clusterin Responses on Survival
CLU Response Definition Population
CLU Response
Outcome
Patients
(n)
Median Survival
(mo)
Hazard Ratio
(95% CI)
Log-Rank test
(p value)
Median minimal level 38 g/ml CLU analysis population Responder 28 27.1 0.5 (0.3–0.9) 0.02
Nonresponder 27 16.1
30-d landmark subpopulation Responder 25 26.0 0.5 (0.3–1.0) 0.04
Nonresponder 24 16.3
Threshold level  45 g/ml CLU analysis population Responder 35 27.1 0.5 (0.3–0.9) 0.02
Nonresponder 20 15.6
CLU, clusterin; CI, confidence interval.
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studies in NSCLC will be required to determine whether
lowering serum CLU is correlated with improved survival
and what, if any, minimal levels are required to observe a
survival benefit.
As anticipated from a regimen containing gemcitabine
and a platinum agent, hematologic toxicity was frequently
observed, and grade 4 toxicity was more common in patients
treated with carboplatin, but few patients required growth
factor or platelet support. Other toxicities of the combined
regimen were not felt to be appreciably different than those
reported for previously published gemcitabine/platinum dou-
blets.29–37 Ninety-six percent of infusion reactions were grade
1 and 2, and reactions only occurred during the 9-day loading
dose period when custirsen concentrations were highest.
Vascular events (CVA, myocardial infarction, pulmonary
embolus, and deep vein thrombosis), common findings in up
to 18% of chemotherapy-treated patients with advanced
NSCLC,38 were seen in 15% of patients. Grade 3/4 lym-
phopenia, seen in 33% of patients, has been reported as a
class effect of ASOs but with no reported clinical sequelae.
CONCLUSION
The effect of custirsen treatment on serum CLU
levels validates the physiologic on-target activity of cu-
stirsen. Demonstrating the potential survival benefit of
custirsen in patients with NSCLC will require results from
a larger randomized phase 3 study, similar to the phase 3
studies currently evaluating custirsen in patients with met-
astatic, castrate-resistant prostate cancer.
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